Clinical Trials · NCT06716216
A Study of BGM0504 in Participants with Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Enrollment
- 537
- Start date
- Nov 2024
- Locations
- 1 site, China
- Primary endpoint
- Change From Baseline in Hemoglobin A1c (HbA1c)